NOT-AI-02-007: PARTNERSHIPS FOR NOVEL THERAPEUTIC, DIAGNOSTIC AND VECTOR CONTROL STRATEGIES IN INFECTIOUS DISEASES

Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health^®

PARTNERSHIPS FOR NOVEL THERAPEUTIC, DIAGNOSTIC AND VECTOR CONTROL STRATEGIES IN 
INFECTIOUS DISEASES - ADDENDUM TO PAR-02-026

Release Date:  January 25, 2002

NOTICE:  NOT-AI-02-007 (also see PAR-02-026, NOT-AI-02-22, NOT-AI-02-013)

National Institute of Allergy and Infectious Diseases
 (http://www.niaid.nih.gov/default.htm)

Receipt Date:  March 20, 2002, NEW June 20, 2002

The National Institute of Allergy and Infectious Diseases is adding 
additional language as well as an additional receipt date to PAR-02-026 
at http://www.niaid.nih.gov/ncn/pa/PAR-02-026.html.

An additional receipt date of June 20,2002 has been added.  

Under Research Objectives and Scope a 4th area will be added:

#4. Development of Vaccines for Selected Agents of Bioterrorism:

Responsive applications to scientific area "4." include those that 
propose to develop vaccines to prevent infection and/or disease from 
CDC Category A agents of bioterrorism (B. anthracis, Clostridium 
botulinum. Yersinia pestis, Variola major, Francisella tularensis and 
causative pathogens of viral hemorrhagic fevers).  Proposed research 
may fall anywhere along a broad spectrum of activities from candidate 
identification and validation through preclinical development and early 
human testing (Phase I and II trials).

Under Review Criteria #1 and #3 have been modified and replaced with 
the following:

1. Significance.  Is this project likely to result in or significantly 
advance development of a novel vaccine, therapeutic or vector control 
agent/strategy or diagnostic technique that will add substantively to 
our ability to prevent diagnose, treat or control an infectious disease 
of public health importance? Is the industry commitment adequate to have 
an impact on the success of the proposed research objectives? If the 
aims of the application are achieved, are important biomedical agents or 
diagnostic technologies likely to result?  What will be the effect of 
these studies on the concepts or methods that drive this field? 

3. Innovation.  Many aspects of vaccine drug, diagnostic and vector 
control method development are not inherently innovative.  However, each 
project will be judged on whether, if successful in completing its aims, 
the project will add substantially to our ability to prevent, diagnose, 
treat or control an infectious disease that currently causes a public 
health burden and is not currently considered an attractive investment 
by the private sector (i.e., biotechnology, chemical or 
pharmaceutical industry).

Complete information about the grant program, PAR-02-026 may be 
obtained at http://grants.nih.gov/grants/guide/pa-files/PAR-02-026.html.

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to 
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic, research scope, and eligibility 
issues to:  

Ann M. Ginsberg, M.D., Ph.D.  
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases  
Room 3133, MSC-7630
6700-B Rockledge Drive
Bethesda, MD  20892-7630
Telephone:  (301) 496-5305
FAX:  (301) 496-8030
E-Mail:  [email protected]
  
Direct inquiries regarding fiscal matters to:  

Ms. Jeanette Gorden                
Division of Extramural Activities  
National Institute of Allergy and Infectious Diseases  
Room 3222, MSC-7614
6700-B Rockledge Drive  
Bethesda, MD  20892-7614
Telephone:  (301) 402-5065
Fax:  (301) 480-3780
E-mail:  [email protected]
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices